ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04363684|
Recruitment Status : Recruiting
First Posted : April 27, 2020
Last Update Posted : September 1, 2021
|Condition or disease|
|Frontotemporal Lobar Degeneration (FTLD) Progressive Supranuclear Palsy (PSP) Corticobasal Degeneration (CBD) Behavioral Variant Frontotemporal Dementia (bvFTD) Semantic Variant Primary Progressive Aphasia (svPPA) Nonfluent Variant Primary Progressive Aphasia (nfvPPA) FTD With Amyotrophic Lateral Sclerosis (FTD/ALS) Amyotrophic Lateral Sclerosis Oligosymptomatic PSP (oPSP) C9orf72 GRN Related Frontotemporal Dementia MAPT Gene Mutation TBK1 Gene Mutation Oligosymptomatic Progressive Supranuclear Palsy|
|Study Type :||Observational|
|Estimated Enrollment :||2100 participants|
|Official Title:||ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)|
|Actual Study Start Date :||March 1, 2020|
|Estimated Primary Completion Date :||July 2024|
|Estimated Study Completion Date :||July 2024|
Annual clinic visits throughout the length of the study.
Single clinic visit.
- Change in Brain Volumes [ Time Frame: Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year ]Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.
- Change in NIH Examiner Executive Composite Score [ Time Frame: Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year ]Evaluate change in NIH Examiner Executive Composite Score in asymptomatic f-FTLD.
- Change in Multidomain Impairment Rating (MIR) Scale [ Time Frame: Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year ]Annual change in MIR score (total score 0-3), which is a new global scale for FTLD that incorporates behavioral, cognitive, and motor dysfunction in the rating.
- Plasma Neurofilament Light Chain Analysis [ Time Frame: 5 years ]Annual blood samples will be collected to detect changes in plasma neurofilament light chain concentrations
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04363684
|Contact: Leah K Forsberg, PhDemail@example.com|
|Contact: Hilary Heuer, PhDfirstname.lastname@example.org|
|Principal Investigator:||Bradley Boeve, MD||Mayo Clinic|
|Principal Investigator:||Adam Boxer, MD, PhD||University of California, San Francisco|
|Principal Investigator:||Howie Rosen, MD||University of California, San Francisco|